U.S., April 30 -- ClinicalTrials.gov registry received information related to the study (NCT07557420) titled 'Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)' on April 23.
Brief Summary: The primary objective of this study is to confirm the efficacy, safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of ravulizumab in the treatment of Chinese adults with anti-aquaporin-4 (AQP4) antibody (Ab) + neuromyelitis optica spectrum disorder (NMOSD).
Study Start Date: Aug. 31, 2026
Study Type: INTERVENTIONAL
Condition:
NMOSD
Neuromyelitis Optica Spectrum Disorder
Intervention:
DRUG: Ravulizumab
Participants...